Lantheus (LNTH) Q1 FY26 earnings call: guidance and Q&A

Why was full-year guidance reaffirmed despite a strong Q1 beat? Is it conservatism, competitive caution, or CEO transition? What is the assumed PSMA PET market growth for 2026?

Management stated that the reaffirmation is due to the early stage of the year, the competitive environment (new products and a competitor losing pass-through in Q4), and prudence given the upcoming CEO transition. They expect PSMA PET market growth for 2026 to be in the low teens, consistent with prior expectations.

“But it's early in the year. And so we're going to remain vigilant to the market, the competitive environment out there. We still have one competitor who is maybe find some footing with their new products, launch themselves as well as one that will be losing pass-through later this year, call it, October 1. So for us, we're going to -- to your point, we're going to be prudent with this.”

asked by Richard Newitter · answered by Robert Marshall

How will the PYLARIFY TRUVU transition work with transitional pass-through (TPT) ruling and contracting? When will TRUVU be completely adopted, and will PYLARIFY Gen 1 be phased out?

PYLARIFY will transition directly to PYLARIFY TRUVU site-by-site, not phased out, to optimize PMF manufacturing. The transition will begin in Q4 2026, contingent on insurance coverage, coding (HCPCS, TPT), and customer systems being ready. Lantheus aims for a seamless transition, leveraging its extensive nuclear medicine experience.

“It will be geographically a site-by-site conversion. As we've offered before, I'll share again that we plan to begin that conversion in Q4 of this year. It's very carefully thought out, and I'll explain why. These products as a class, PET diagnostic products are uniformly prior authorized.”

asked by Anthony Petrone · answered by Mary Heino

What strategies are being used for customer readiness for TRUVU, and what lessons from the original PYLARIFY launch are being applied to mitigate adoption hurdles?

The strategy focuses on making the transition 'invisible' to customers by ensuring seamless dose delivery, reimbursement, and coverage. Lantheus will leverage its portfolio approach and nuclear medicine relationships. Operational steps include securing FDA approvals for PMF sites and conducting validation batches, drawing confidence from the successful original PYLARIFY launch.

“This is a master piece of preparation because before the first dose and from our customers' perspective, all we want them to see is that their dose shows up and that the coverage and payment, the reimbursement for it has already been fully approved.”

asked by Roanna Clarissa Ruiz · answered by Mary Heino

Can you discuss the pricing strategy for TRUVU with TPT and its potential impact on 2027?

Management declined to discuss specific pricing strategy. They noted that transitional pass-through (TPT) is a reimbursement mechanism for hospital outpatient settings and traditional fee-for-service Medicare patients, and the focus is on ensuring hospital customers are aware of this. While 2027 guidance will be provided later, it is expected to be a year of growth acceleration.

“What I will say and what I think all of you from working so closely with us over the years are aware of is that transitional pass-through is a reimbursement mechanism that's available only in the hospital outpatient setting and only applies to traditional fee-for-service Medicare patients.”

asked by Matthew Taylor · answered by Mary Heino

What percentage of the PMF network is equipped with high-energy cyclotrons for TRUVU, and will all transition? What are the implications for supply ramp-up and production?

Approximately 70% of the current PMF network that services PYLARIFY already has high-energy cyclotrons. TRUVU requires different cassettes for the synthesis boxes, not a hardware transition of the cyclotrons themselves. The success of PET imaging agents has invigorated investment in the PMF network, ensuring operational readiness.

“But when we look out at what the current PMF network is that services PYLARIFY and will service PYLARIFY TRUVU in the future, we estimate that already 70% of that, and I'll call it a fleet. It's a fleet of manufacturing sites. We estimate that 70% of our fleet is already serviced by high energy cyclotrons.”

asked by Tsan-Yu Hsieh · answered by Mary Heino

Can you provide an update on the NEURACEQ market landscape, its share relative to competitors, and expectations for increased attach rates to disease-modifying therapies (DMTs) in the back half of the year?

NEURACEQ is the fastest-growing and holds the second-highest share among beta amyloid imaging agents. Lantheus is investing in expanded availability, deeper penetration in existing accounts, and expanding its PMF footprint to 22 sites. The product is benefiting from a large and expanding market, the adoption of Alzheimer's DMTs, and clinical guidelines favoring earlier diagnostic use.

“First, -- it is the fastest agent growing of the 3 agents that are currently present in the market. And second, it holds the second highest share already in that market.”

asked by Anthony Petrone · answered by Mary Heino